Contact
searchSearch
HMP Global
Login
Video Thumbnail
Videos
Emerging Data on Alpha-Emitter Therapies
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts reflect on evolving roles of alpha and beta emitters, novel isotopes in development, and the balance between efficacy and toxicity that will define next-generation radioligand therapy.
Experts reflect on evolving roles of alpha and beta emitters, novel isotopes in development, and the balance between efficacy and toxicity that will define next-generation radioligand therapy.
Experts reflect on evolving...
11/18/2025
Radiopharmaceutical Education Institute
Video Thumbnail
Videos
Mechanism of Action: Beta vs Alpha Emitters
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts analyze early and long-term data from ALPHAMEDIX-02 and other alpha-emitter trials, including efficacy, toxicity patterns, and key differences between actinium- and lead-based compounds.
Experts analyze early and long-term data from ALPHAMEDIX-02 and other alpha-emitter trials, including efficacy, toxicity patterns, and key differences between actinium- and lead-based compounds.
Experts analyze early and...
11/18/2025
Radiopharmaceutical Education Institute
Video Thumbnail
Videos
Practical Application and Patient Selection for PRRT
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
The panel examines tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs.
The panel examines tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs.
The panel examines tumor...
11/18/2025
Radiopharmaceutical Education Institute
Video Thumbnail
Videos
Examining the Evidence for Lutetium-Based PRRT
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts discuss data from pivotal trials that evaluated progression-free survival outcomes, treatment sequencing, and considerations for first-line PRRT use.
Experts discuss data from pivotal trials that evaluated progression-free survival outcomes, treatment sequencing, and considerations for first-line PRRT use.
Experts discuss data from...
11/18/2025
Radiopharmaceutical Education Institute
Video Thumbnail
Videos
The Current NET Treatment Landscape and Unmet Needs
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts review the evolving treatment landscape for neuroendocrine tumors (NETs), highlighting approved systemic and liver-directed therapies and ongoing challenges in treatment sequencing.
Experts review the evolving treatment landscape for neuroendocrine tumors (NETs), highlighting approved systemic and liver-directed therapies and ongoing challenges in treatment sequencing.
Experts review the evolving...
11/18/2025
Radiopharmaceutical Education Institute
News
177Lu-Edotreotide Extends Progression-Free Survival vs Everolimus in GEP-NETs
10/28/2025
Janelle Bradley
¹⁷⁷Lu-edotreotide significantly improved progression-free survival and objective response rates compared to everolimus in patients with advanced GEP-NETs, with consistent benefits across tumor grades, sites, and prior treatment settings,...
¹⁷⁷Lu-edotreotide significantly improved progression-free survival and objective response rates compared to everolimus in patients with advanced GEP-NETs, with consistent benefits across tumor grades, sites, and prior treatment settings,...
¹⁷⁷Lu-edotreotide significantly...
10/28/2025
Radiopharmaceutical Education Institute
News
Obrixtamig Demonstrates Promising Efficacy in DLL3-High Extrapulmonary Neuroendocrine Carcinoma
10/28/2025
Janelle Bradley
Obrixtamig, a DLL3/CD3 bispecific T-cell engager, demonstrated a 40% objective response rate and durable, manageable activity in patients with DLL3-high extrapulmonary neuroendocrine carcinoma, according to a phase 1 trial.
Obrixtamig, a DLL3/CD3 bispecific T-cell engager, demonstrated a 40% objective response rate and durable, manageable activity in patients with DLL3-high extrapulmonary neuroendocrine carcinoma, according to a phase 1 trial.
Obrixtamig, a DLL3/CD3...
10/28/2025
Oncology
News
TAE and cTACE Show Comparable Efficacy for Liver-Dominant Neuroendocrine Tumor Metastases
10/28/2025
Janelle Bradley
Findings from an international randomized trial show transarterial embolization (TAE) and conventional chemoembolization (cTACE) demonstrated comparable efficacy for liver-dominant neuroendocrine tumor metastases, though TAE was associated...
Findings from an international randomized trial show transarterial embolization (TAE) and conventional chemoembolization (cTACE) demonstrated comparable efficacy for liver-dominant neuroendocrine tumor metastases, though TAE was associated...
Findings from an international...
10/28/2025
Oncology
News
212Pb-DOTAMTATE Demonstrates Promising Activity After Prior PRRT in Advanced GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE achieved a 30.8% objective response rate and a 96% disease control rate with a manageable safety profile in patients with advanced SSTR-positive GEP-NETs who had progressed following prior...
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE achieved a 30.8% objective response rate and a 96% disease control rate with a manageable safety profile in patients with advanced SSTR-positive GEP-NETs who had progressed following prior...
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
News
212Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute

About

The NANETS Annual Symposium provides a dedicated space for medical and research professionals to exchange insights, explore innovative techniques, and collaborate on the future of NET diagnosis and treatment.

This three-day event is designed by medical professionals, for medical professionals, and remains the leading annual educational conference focused exclusively on NET disease.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use